US Patent Issued to AVIRMAX on Oct. 14 for "Host cell including expression vector for encoding catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants" (California Inventor)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,441,990, issued on Oct. 14, was assigned to AVIRMAX INC. (Hayward, Calif.).

"Host cell including expression vector for encoding catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants" was invented by Shengjiang Liu (Hayward, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Angiotensin-converting enzyme 2(ACE2) has been confirmed as a specific receptor for several Beta group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in Alpha-coronavirus group. Viral spike protein (S...